F2G Stock

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

Sign up today and learn more about F2G Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About F2G Stock

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Funding History

September 2002$4.3M
July 2004$5.5M
February 2006$115K
March 2006$5.0M
August 2008$6.3M
September 2012$30.0M
September 2014$1.4M
June 2016$60.0M
November 2018$24.0M
August 2020$60.8M


Chief Executive Officer

Ian Nicholson

Chief Scientific and Development Officer

Tony Kennedy

Chief Operating Officer

Mike Birch

Non Executive Director

Christopher Wright

Non Executive Director

Raj Parekh

Board Member

Naveed Siddiqi

Board Observer

Eric Richman

Chairman of the Board

Richard White

Board Of Director

Maha Katabi


George Drusano

Chief Medical Officer

John H. Rex


Ralf Schmid

Board Of Director

Martin Edwards

Member of the Board of Advisor

Mitchell Kurk

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: